Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

A recent The New York Times piece peeled back the cover on the e-sport you didn't know you were missing: the Microsoft Excel World Championship. Last month in Las Vegas, 12 men ran through a pro ...

Budgeting can feel overwhelming, but it doesn't have to be. While there is no shortage of finance apps, nothing beats the ...

At the Microsoft Excel World Championship in Las Vegas, there was stardust in the air as 12 finance guys vied to be crowned the world’s best spreadsheeter. transcript The event’s organizer ...

Microsoft has introduced lots of new features to its Excel app recently, aimed at enhancing productivity, simplifying data analysis, and improving usability across desktop, web, Mac, and iPad ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...